1. Home
  2. RDNW vs IPHA Comparison

RDNW vs IPHA Comparison

Compare RDNW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RideNow Group Inc.

RDNW

RideNow Group Inc.

HOLD

Current Price

$6.37

Market Cap

235.4M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.78

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RDNW
IPHA
Founded
2013
1999
Country
United States
France
Employees
1906
163
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.4M
165.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RDNW
IPHA
Price
$6.37
$1.78
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$6.50
$5.75
AVG Volume (30 Days)
147.1K
6.3K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.01
$180.36
Revenue Next Year
$6.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.98
$1.18
52 Week High
$8.55
$2.63

Technical Indicators

Market Signals
Indicator
RDNW
IPHA
Relative Strength Index (RSI) 49.28 52.60
Support Level $6.28 $1.73
Resistance Level $6.58 $1.96
Average True Range (ATR) 0.33 0.05
MACD 0.09 -0.00
Stochastic Oscillator 84.95 39.78

Price Performance

Historical Comparison
RDNW
IPHA

About RDNW RideNow Group Inc.

RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: